1. Home
  2. MGN vs PCSA Comparison

MGN vs PCSA Comparison

Compare MGN & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MGN

Megan Holdings Limited Ordinary Shares

BUY

Current Price

$2.13

Market Cap

4.5M

Sector

N/A

ML Signal

BUY

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$1.77

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGN
PCSA
Founded
2020
2011
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
4.2M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
MGN
PCSA
Price
$2.13
$1.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
123.4K
★ 173.3K
Earning Date
11-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $5,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.33
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.06
$0.11
52 Week High
$5.18
$8.88

Technical Indicators

Market Signals
Indicator
MGN
PCSA
Relative Strength Index (RSI) 39.20 49.92
Support Level $0.11 $1.04
Resistance Level $2.19 $2.00
Average True Range (ATR) 0.36 0.21
MACD -0.26 0.04
Stochastic Oscillator 7.58 75.51

Price Performance

Historical Comparison
MGN
PCSA

About MGN Megan Holdings Limited Ordinary Shares

Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Share on Social Networks: